ACADIA Historical Income Statement
ACAD Stock | USD 18.20 0.41 2.30% |
Historical analysis of ACADIA Pharmaceuticals income statement accounts such as Selling General Administrative of 426.9 M, Total Revenue of 762.8 M or Gross Profit of 714.7 M can show how well ACADIA Pharmaceuticals performed in making a profits. Evaluating ACADIA Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ACADIA Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ACADIA Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ACADIA Pharmaceuticals is a good buy for the upcoming year.
ACADIA |
About ACADIA Income Statement Analysis
ACADIA Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ACADIA Pharmaceuticals shareholders. The income statement also shows ACADIA investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ACADIA Pharmaceuticals Income Statement Chart
ACADIA Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting ACADIA's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ACADIA Pharmaceuticals revenue and expense. ACADIA Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, ACADIA Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 762.8 M, whereas EBIT is forecasted to decline to (77 M). Add Fundamental
Total Revenue
Total revenue comprises all receipts ACADIA Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of ACADIA Pharmaceuticals minus its cost of goods sold. It is profit before ACADIA Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ACADIA Pharmaceuticals. It is also known as ACADIA Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from ACADIA Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 762.8 M, whereas EBIT is forecasted to decline to (77 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 465.0M | 507.1M | 680.7M | 714.7M | Total Revenue | 484.1M | 517.2M | 726.4M | 762.8M |
ACADIA Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
ACADIA Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ACADIA Pharmaceuticals income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 14.9M | 8.5M | 6.3M | 6.6M | 7.6M | 8.0M | |
Selling General Administrative | 325.6M | 388.7M | 396.0M | 369.1M | 406.6M | 426.9M | |
Total Revenue | 339.1M | 441.8M | 484.1M | 517.2M | 726.4M | 762.8M | |
Gross Profit | 319.5M | 421.2M | 465.0M | 507.1M | 680.7M | 714.7M | |
Other Operating Expenses | 585.6M | 728.3M | 654.6M | 740.8M | 799.8M | 839.8M | |
Operating Income | (246.5M) | (286.6M) | (170.4M) | (223.6M) | (73.4M) | (77.0M) | |
Ebit | (246.5M) | (286.6M) | (170.4M) | (223.6M) | (73.4M) | (77.0M) | |
Research Development | 240.4M | 319.1M | 239.4M | 361.6M | 351.6M | 369.2M | |
Ebitda | (243.8M) | (283.7M) | (167.1M) | (221.6M) | (67.8M) | (71.2M) | |
Total Operating Expenses | 566.0M | 707.8M | 635.4M | 730.7M | 754.1M | 791.8M | |
Net Income | (235.3M) | (281.6M) | (167.9M) | (216.0M) | (61.3M) | (64.4M) | |
Income Tax Expense | 876K | 611K | 351K | 2.5M | 10.3M | 10.8M | |
Depreciation And Amortization | 2.8M | 2.9M | 3.3M | 2.0M | 5.6M | 5.8M | |
Cost Of Revenue | 19.6M | 20.6M | 19.1M | 10.2M | 45.7M | 25.9M | |
Income Before Tax | (234.4M) | (281.0M) | (167.5M) | (213.4M) | (51.0M) | (53.6M) | |
Total Other Income Expense Net | 12.2M | 5.6M | 2.9M | 10.2M | 22.3M | 23.5M | |
Net Income Applicable To Common Shares | (235.3M) | (281.6M) | (167.9M) | (216.0M) | (194.4M) | (204.1M) | |
Net Income From Continuing Ops | (235.3M) | (281.6M) | (167.9M) | (216.0M) | (61.3M) | (64.4M) | |
Tax Provision | 876K | 611K | 351K | 2.5M | 10.3M | 10.8M | |
Interest Income | 5.3M | 11.2M | 6.6M | 591K | 17.2M | 18.1M | |
Net Interest Income | 5.3M | 11.2M | 6.6M | 591K | 17.2M | 18.1M | |
Reconciled Depreciation | 2.8M | 2.9M | 3.3M | 2.0M | 5.6M | 3.5M |
Pair Trading with ACADIA Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ACADIA Stock
0.75 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
0.65 | MBRX | Moleculin Biotech Upward Rally | PairCorr |
0.93 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against ACADIA Stock
0.9 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.83 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
0.79 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
0.72 | TCRX | Tscan Therapeutics Financial Report 8th of May 2024 | PairCorr |
0.64 | MRK | Merck Company Fiscal Quarter End 31st of March 2024 | PairCorr |
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.